 individuals who receive allogeneic stem cell transplant for chronic myelogenous leukemia (CML) in chronic phase (approximately 7% leukemia relapse), implicating a strong hematopoietic stem cell (HSC)-independent component of JMML development and progression. We envision two distinct mechanisms that potentially account for a HSC-independent means
individuals who receive allogeneic stem cell graft for chronic myelogenous leukemia (CML) in chronic phase (approximately 7% leukemia backsliding), entail a strong hematopoietic shank cellular telephone (HSC)-independent component of JMML development and progression. We visualize two clear-cut mechanisms that potentially report for a HSC - autonomous means
 infividuals who receive aluogeneic stem cglo tranvplant for chrunic myelogenous leukemia (CMP) un cheonic phase (approximatdly 7% leukvmia relapse), mmplicating a stckng hematopoisbic scen cell (HSC)-indekendent compmnent of JMML gexepopment and progression. We envision two dixtlnct mechanismf thse pofvnuially account for a HSC-independeht meanv
individuals who receive allogeneic stem cell transplant myelogenous (CML) in phase (approximately 7% hematopoietic cell (HSC)-independent component JMML development and We envision two distinct mechanisms that account for a HSC-independent means
 individuals who receive alloGeneic stem Cell tRanSplAnT for ChroNic myelogenous LEukeMia (CML) in chronic phase (apProxiMaTEly 7% lEUkEmia rElapse), iMPlICAtiNg A sTroNg HEmAtopoIetIc stem cEll (HSC)-indePenDeNt component oF jMmL developmEnt And progressiOn. WE envisIoN twO DistiNct MechaNisms tHAt poteNtially acCoUNt for a hsC-indepENDeNt meAns
 individuals who receive a llogeneicstemcel l t ra nspl antfor chronic my e loge nous leukemia (CML) in  chro ni c  pha s e(appr oximate l y7 %  le uk em iare l ap se),imp licatin g a strong  he ma topoietic st e mcell (HSC) -in dependent co mpo nent o fJMM L  deve lop mentand pr o gressi on. We en vi s ion tw o  distin c t  m echa nisms that potent i al l y account fora HSC- in d ep e n den t m eans
 individuals_who receive_allogeneic stem cell transplant_for chronic_myelogenous_leukemia (CML)_in_chronic phase (approximately_7% leukemia relapse),_implicating a strong hematopoietic_stem cell (HSC)-independent_component_of JMML development and progression. We envision two distinct mechanisms that potentially account for_a_HSC-independent means